Acumen Pharmaceuticals Rings the Closing Bell
ABOUT THIS EVENT
Acumen Pharmaceuticals, Inc. (Nasdaq: ABOS), a clinical stage biopharmaceutical company focused on the development of novel targeted therapeutics for Alzheimer’s disease (AD), visits the Nasdaq MarketSite in Times Square.
In honor of the occasion, Daniel O’Connell, President and Chief Executive Officer at Acumen, rings the Closing Bell.